Head-To-Head Analysis: Pathfinder Cell Therapy (OTCMKTS:PFND) & Heart Test Laboratories (NASDAQ:HSCS)

Heart Test Laboratories (NASDAQ:HSCS) and Pathfinder Cell Therapy (OTCMKTS:PFND) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Profitability

This table compares Heart Test Laboratories and Pathfinder Cell Therapy’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Heart Test Laboratories	N/A	-144.12%	-94.48%
Pathfinder Cell Therapy	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current recommendations for Heart Test Laboratories and Pathfinder Cell Therapy, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heart Test Laboratories	0	0	1	0	3.00
Pathfinder Cell Therapy	0	0	0	0	0.00

Heart Test Laboratories currently has a consensus target price of $15.00, indicating a potential upside of 289.61%. Given Heart Test Laboratories’ stronger consensus rating and higher probable upside, research analysts clearly believe Heart Test Laboratories is more favorable than Pathfinder Cell Therapy.

Valuation and Earnings

This table compares Heart Test Laboratories and Pathfinder Cell Therapy”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heart Test Laboratories	$18,600.00	188.98	-$6.61 million	($21.64)	-0.18
Pathfinder Cell Therapy	N/A	N/A	N/A	N/A	N/A

Pathfinder Cell Therapy has lower revenue, but higher earnings than Heart Test Laboratories.

Institutional & Insider Ownership

17.2% of Heart Test Laboratories shares are held by institutional investors. 1.8% of Heart Test Laboratories shares are held by company insiders. Comparatively, 15.1% of Pathfinder Cell Therapy shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Heart Test Laboratories beats Pathfinder Cell Therapy on 5 of the 8 factors compared between the two stocks.

About Heart Test Laboratories

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

About Pathfinder Cell Therapy

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.